These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 8067203)

  • 1. [Molecular basis of chronic granulocytic leukemia: from test-tube to patient].
    Skórski T
    Acta Haematol Pol; 1994; 25(2 Suppl 1):184-91. PubMed ID: 8067203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia.
    Deininger MW; Vieira S; Mendiola R; Schultheis B; Goldman JM; Melo JV
    Cancer Res; 2000 Apr; 60(7):2049-55. PubMed ID: 10766197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Leukemogenesis and new therapy development: the example of chronic myelogenous leukemia].
    Etienne G; Mahon FX
    Bull Cancer; 2001 Jul; 88(7):651-8. PubMed ID: 11495816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts.
    Deininger MW; Vieira SA; Parada Y; Banerji L; Lam EW; Peters G; Mahon FX; Köhler T; Goldman JM; Melo JV
    Cancer Res; 2001 Nov; 61(21):8005-13. PubMed ID: 11691826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia.
    Salesse S; Verfaillie CM
    Oncogene; 2002 Dec; 21(56):8547-59. PubMed ID: 12476301
    [No Abstract]   [Full Text] [Related]  

  • 6. Rational approaches to the design of therapeutics targeting molecular markers: the case of chronic myelogenous leukemia.
    Saglio G; Morotti A; Mattioli G; Messa E; Giugliano E; Volpe G; Rege-Cambrin G; Cilloni D
    Ann N Y Acad Sci; 2004 Dec; 1028():423-31. PubMed ID: 15650267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phosphatidylinositol-3 kinase and the protein network of BCR/ABL oncogenic tyrosine kinase.
    Ren SY; Xue F; Feng J; Skorski T
    Exp Hematol; 2005 Oct; 33(10):1222-8. PubMed ID: 16219545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
    Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
    Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanisms of Bcr-Abl-induced oncogenesis.
    Gishizky ML
    Cytokines Mol Ther; 1996 Dec; 2(4):251-61. PubMed ID: 9384712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense inhibition of P210 bcr-abl in chronic myeloid leukemia.
    Vaerman JL; Lewalle P; Martiat P
    Stem Cells; 1993 Oct; 11 Suppl 3():89-95. PubMed ID: 8298481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCR-ABL in chronic myelogenous leukemia--how does it work?
    Goldman JM; Melo JV
    Acta Haematol; 2008; 119(4):212-7. PubMed ID: 18566539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanisms of transformation by the BCR-ABL oncogene.
    Sattler M; Griffin JD
    Semin Hematol; 2003 Apr; 40(2 Suppl 2):4-10. PubMed ID: 12783368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
    Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
    Usui N
    Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
    Jabbour E; Cortes J; Kantarjian H
    Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
    Jilani I; Kantarjian H; Gorre M; Cortes J; Ottmann O; Bhalla K; Giles FJ; Albitar M
    Leuk Res; 2008 Apr; 32(4):643-9. PubMed ID: 17900686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New approach in the diagnosis and monitoring of treatment in chronic myelogenous leukemia].
    Matolcsy A
    Orv Hetil; 2004 Dec; 145(52):2603-9. PubMed ID: 15724695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression analysis of BCR/ABL1-dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation.
    Håkansson P; Nilsson B; Andersson A; Lassen C; Gullberg U; Fioretos T
    Genes Chromosomes Cancer; 2008 Apr; 47(4):267-75. PubMed ID: 18181176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Leucemogenesis of chronic myelogenous leukemia].
    Mahon FX
    Rev Prat; 2005 Oct; 55(15):1642-6. PubMed ID: 16334200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemia.
    Arlinghaus RB
    Oncogene; 2002 Dec; 21(56):8560-7. PubMed ID: 12476302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.